Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Titel:
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Döhner, Hartmut Weber, Daniela Krzykalla, Julia Fiedler, Walter Kühn, Michael W M Schroeder, Thomas Mayer, Karin Lübbert, Michael Wattad, Mohammed Götze, Katharina Fransecky, Lars Koller, Elisabeth Wulf, Gerald Schleicher, Jan Ringhoffer, Mark Greil, Richard Hertenstein, Bernd Krauter, Jürgen Martens, Uwe M Nachbaur, David Samra, Maisun Abu Machherndl-Spandl, Sigrid Basara, Nadezda Leis, Claudia Schrade, Anika Kapp-Schwoerer, Silke Cocciardi, Sibylle Bullinger, Lars Thol, Felicitas Heuser, Michael Paschka, Peter Gaidzik, Verena I Saadati, Maral Benner, Axel Schlenk, Richard F Döhner, Konstanze Ganser, Arnold